hCAI/II-IN-6

Research use only, not for human use.

hCAI/II-IN-6 is a selective and orally active inhibitor of human carbonic anhydrase (CA). hCAI/II-IN-6 inhibited hCA I, hCA II, hCA VII, and hCA XII with Ki values of 220, 4.9, 6.5, and ＞50,000 nM.

hCAI/II-IN-6 is an orally active human carbonic anhydrase (CA) inhibitor. hCAI/II-IN-6 selectively inhibits hCA II and hCA VII isoforms with Ki values of 220, 4.9, 6.5 and ＞50000 nM for hCA I, hCA II , hCA VII and hCA XII respectively. hCAI/II-IN-6 shows anticonvulsant activity and anti maximal electroshock (MES) activity in vivo. hCAI/II-IN-6 can be used for the research of epilepsy.

hCAI/II-IN-6 (0-50 μM) inhibits hCA I, hCA II , hCA VII and hCA XII activities with Ki values of 220, 4.9, 6.5 and ＞50000 nM, respectively.

hCAI/II-IN-6 (30-100mg/kg; i.p. once) shows good anticonvulsant effect in vivo.hCAI/II-IN-6 (30 mg/kg; p.o. once) shows anti-MES activity in vivo.Animal Model:Swiss albino miceDosage:30 and 100 mg/kg Administration:Intraperitoneal injection; 30-100 mg/kg once Result:Provided seizure attenuation and good anticonvulsant effect, and showed an ED50 of 13.7mg/kg in anticonvulsant quantification study.Animal Model: Wistar albino rats Dosage:30 mg/kg Administration:Oral gavage; 30 mg/kg once Result:Showed anti-MES activity and significant protection from seizures up to 1h of drug administration and action was gone reduced after 1h.

——

Membrane Transporter/Ion Channel

Carbonic Anhydrase

Carbonic Anhydrase

——

——

694466-00-7

388.48

C19H24N4O3S

>98% (HPLC)

In Vitro:?DMSO : 250 mg/mL (643.53 mM; Ultrasonic )

NS(=O)(=O)c1ccc(NC(=O)CN2CCN(Cc3ccccc3)CC2)cc1

——

(-20℃)

With Ice Pack

≥ 2 years